The PURPOSE of Sickle Treatment and Outcomes Research in the Midwest (STORM) is to bring together the hematology and primary care communities to collaborate with patients and families on quality improvement initiatives to improve access and delivery of care and outcomes for patients with sickle cell disease (SCD) in the Midwest.
Our APPROACH is a collaborative effort that implements quality improvement projects with pediatric and adult hematology practices to build a sustainable network to improve the outcomes and care for patients with sickle cell disease (SCD) in the Midwest. STORM participation is at the institution level or practice level, whereas each participating institution identifies a lead physician and additional clinical faculty and staff who work as members of local site-specific and topic-specific improvement teams.
The Midwest region consists of six states (IL, IN, MI, MN, OH, & WI) with a total population of roughly 52 million. A recent study found that there are approximately 15,000 individuals with SCD in the Midwest. It is estimated over 700,000 African Americans and 35,000 Hispanic individuals with sickle cell trait live in this region 1. The six states listed above have joined together to design, implement, and evaluate a project that will effectively engage our regional state partners and patients in a collaborative network to improve outcomes for all individuals with SCD in the Midwest.
An official document describing the mission of the project/team and how the mission will be accomplished. The charter empowers the team to act and includes the aim statement, timelines, project sponsor, methods, and more.
A quality improvement (QI) tool used to define a project’s aim and identify the “drivers” needed to achieve the aim. The KDD allows the project team to have a common language and focus.
A concise summary of the project used as a communication tool for informing both internal and external audiences of the overall project.